0001213900-17-010915.txt : 20171025 0001213900-17-010915.hdr.sgml : 20171025 20171025105057 ACCESSION NUMBER: 0001213900-17-010915 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171025 FILED AS OF DATE: 20171025 DATE AS OF CHANGE: 20171025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Therapix Biosciences Ltd. CENTRAL INDEX KEY: 0001611746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1213 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38041 FILM NUMBER: 171152320 BUSINESS ADDRESS: STREET 1: 4 ARIEL SHARON STREET STREET 2: HASHAHAR TOWER, 16TH FLOOR CITY: GIV?ATAYIM STATE: L3 ZIP: 5320047 BUSINESS PHONE: 972-3-6167055 MAIL ADDRESS: STREET 1: 4 ARIEL SHARON STREET STREET 2: HASHAHAR TOWER, 16TH FLOOR CITY: GIV?ATAYIM STATE: L3 ZIP: 5320047 6-K 1 f6k102517_therapixbios.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2017 (Report No. 1)

Commission file number: 001- 38041

Therapix Biosciences Ltd.

(Translation of registrant’s name into English)

4 Ariel Sharon Street

HaShahar Tower, 16th Floor

Giv’atayim 5320047, Israel

Tel: 972-3-6167055, Fax: 972-3-6167056

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐ No ☑

On October 25, 2017, Therapix Biosciences Ltd. (“Therapix”) convened its previously announced 2017 Annual General Meeting of Shareholders (the “Annual Meeting”). However, the quorum of three or more shareholders present, personally or by proxy, who hold or represent together more than 30% of the voting rights of Therapix’s issued share capital required to conduct the Annual Meeting was not present. Accordingly, pursuant to Therapix’s articles of association, the Annual Meeting has been adjourned to November 1, 2017. The adjourned Annual Meeting will be held at Therapix’s offices at 4 Ariel Sharon Street, HaShahar Tower, 16th Floor, Giv’atayim 5320047, Israel at 3:00 p.m. (Israel time).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Therapix Biosciences Ltd. (Registrant)

	By	/s/ Josh Blacher
	Name:	Josh Blacher
	Title:	Chief Financial Officer

Date: October 25, 2017